Faricimab Biosimilar – Anti-ANGPT2, VEGFA mAb – Research Grade

About Faricimab biosimilar

Faricimab is a bispecific monoclonal antibody. This antibody is especially part of the human immunoglobulin G1-kappa-lambda type. It is targeting angiopoetin 2 (ANGPT2) and Vascular Endothelial Growth factor A (VEGFA). Both of these factors play key roles in angiogenesis and endothelial development respectively. Angiopoetin 2 is essential for normal vascular development as VEGF-A, which is an endothelial cell mitogen. Angiopoetin 2 is involved especially in vascular morphogenesis and homeostasis, and is mostly expressed in endothelial cells.
The expression of VEGF-A is shown to be up regulated in inflamed and vascularized human corneas. VEGF-A is therefore a target of choice to treat patients with retinal vascular diseases such as a retinal vein occlusion, Age related macular degeneration (AMD) and diabetic macular edema. Indeed, these diseases are caused by retinal ischemia and subsequent neovascularization.

A research grade biosimilar

Faricimab biosimilar is a humanized antibody based on on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use.